Objectives. To investigate the perception of and treatment pattern with regard to the four important issues in the management of lupus nephritis (LN), and to identify which parts of the LN treatment are difficult for physicians to carry out in clinical practice. Methods. Four steps were carried out: pre-survey, LN symposium, post-survey, and meeting after the symposium.The two surveys were conducted with the same contents regarding renal biopsy, induction and maintenance treatment for class III and IV LN, and treatment for class V LN. The results of the first survey and the changes in opinion reflected in the second survey were comparatively analyzed. Results. In the first survey, most of the respondent physicians replied that they would immediately conduct biopsy in the case of significant proteinuria. For the induction treatment of class III and IV LN, most of the respondent physicians selected high-dose cyclophosphamide. Mycophenolate mofetil and steroid combination therapy were selected for the maintenance treatment, and tacrolimus for the treatment of class V LN. There was a controversy in the drug selection, however, especially on the maintenance treatment of class III and IV LN and on the treatment of non-responsive class V LN. Conclusion. Some discrepancies were found in the treatment of LN in the real world. Although no recommendation was made for Korean LN patients in this study, the study results will help physicians select the most reasonable treatment for Korean LN patients based on experts' experiences and objective evidence.
Introduction
Renal involvement is observed in 50∼75% of patients with systemic lupus erythematosus (SLE) within 10 years after the disease occurrence (1, 2) . As it may reduce a patient's survival, active proper treatment is required (3) . Renal-function main- This study is a preliminary step towards establishing a recommendation for the treatment of LN in Koreans. Understanding physicians' attitudes and preferences regarding the treatment of LN is step in developing effective guidelines for such treatment and may also help overcome the barriers to guideline implementation.
In this study, a pre-survey was conducted, and a symposium on LN was held, followed by a post-survey regarding the four important issues related to LN that came about due to the absence of definite guidelines for its treatment in Koreans. The purpose of the study was to help physicians select the most reasonable and feasible treatment for Korean LN patients based on experts' experiences and objective evidence.
Matherials and Methods
A steering committee consisting of nine rheumatologists was organized for the conduct of the study. They were responsible for identifying the important issues related to the treatment of LN, developing clinical scenarios related to such issues, reviewing related articles and presentations, and analyzing the survey results. The study was conducted in four steps (Figure 1 ).
Step 1: pre-survey on the issues related to the treatment of LN (first survey) : The steering committee selected four topics, as follows: initial renal biopsy, induction treatment of class III and IV LN, maintenance treatment of class III and IV LN, and treatment of class V LN. They developed four patient scenarios and multiple choice items on how to manage the four imaginary patients and on the suitable evidence for the treatment decision. A pre-survey was conducted among rheumatologists via the Internet in October 2011.
Step 2: symposium on the management of LN: The symposium was held on October 28, 2011. In the symposium, a systematic review of the above four topics was carried out (details in the supplementary information).
Step 3: post-survey on the same issues related to the treatment of LN (second survey): To assess the changes in the LN treatment policy agreed upon by the physicians, a second survey was conducted via the Internet in November 2011. The survey participants were those who attended the symposium, and the patient scenarios and questionnaires that were used in the pre-survey were likewise used in the second survey.
Step 4: analysis of the results of the two surveys by the steering committee after the symposium: After the symposium, the steering committee analyzed the results of the two surveys and reviewed the presentation, questions, and arguments raised in the symposium to summarize the current trends, problems, and perspectives on the treatment of Korean LN patients.
Statistical analysis
The results of the first survey, which were especially stratified by experience in lupus patient care, were analyzed. Then the differences between the results of the two surveys were comparatively analyzed using only the answers of the physicians who participated in both the first and second surveys.
All the results are reported herein as means and standard deviations (SDs) or frequencies (%). The categorical variables were compared via Chi-square test or Fisher's exact test, as appropriate, and independent sample t-tests were used to compare 
Results
Characteristics of the physicians who participated in the symposium and surveys 
First renal biopsy
Results of the first survey: In the first scenario, the LN patient was taking 60 mg/day prednisolone orally following steroid pulse therapy for the treatment of neuropsychiatric lupus. The survey participants were asked to indicate the appropriate time for performing renal biopsy in the LN patient (Table 2-1).
They answered as follows: 54% (n=26) of the respondents would perform renal biopsy immediately. The frequency of such answer was significantly higher in the physicians who had less than five years experience than in the physicians who had five years experience or more (p≤.001). About 23% (n=11) would perform renal biopsy if there was no response to the additional immunosuppressant, which answer was significantly higher in the physicians who had five years experience or more (p≤.001). Ten percent (n=5) would perform renal biopsy after decreasing the dose of steroids to 20 mg/day or less, and 4% (n=2) would omit biopsy (Table 3 and Figure   2A ). For the evidence that would make them decide to conduct biopsy or not to, the participants cited the recent international clinical guidelines (n=13, 27.1%), the published results of clinical studies (n=12, 25%), and the presentations in the symposium and the meeting (n=10, 20.8%).
Comparison of the results of the first and second surveys: A second survey was conducted to investigate the changes in the physicians' LN treatment selection after the symposium, which provided evidence of the efficacy of such method. No Table 2 . Clinical scenarios and questionnaires of the surveys conducted before and after the symposium 2-1. When would you conduct renal biopsy to determine the treatment method for the patient? A 35-year-old woman patient with lupus was referred to the Emergency Department due to systemic tonic-clonic seizure. As the MRI T2 weighted image showed a contrast-increasing lesion on the white matter, the patient was diagnosed with neuropsychiatric lupus. The patient was made to take 60 mg/d prednisolone orally after steroid pulse therapy (1 g/d methylprednisolone for five days), after which the seizure improved, without recurrence. Despite the improvement shown in the neuropsychiatric lupus with the treatment, however, a spot urine protein creatinine ratio of 1.5 was still present in her urinalysis. 2-2. Which drug would you select first when considering further treatment of this patient?
A 25-year-old woman patient with lupus visited the hospital due to edema. Her blood chemistry showed the following results: BUN25 mg/dL, creatinine 1.0 mg/dL, C3/C4 21/7 mg/dL, and 24 h proteinuria 4.5 g. The renal biopsy showed that the patient had class IV LN. 2-3. Which drug would you select for maintenance treatment of this patient?
A 38-year-old woman patient who visited the hospital due to generalized edema was diagnosed with class IV LN. She hada spot urine protein creatinine ratio of 8.0 and a serum creatinine level of 1.4 mg/dl. After induction treatment using high-dose CYC according to the NIH protocol, she had a spot urine protein creatinine ratio of 0.4, a serum creatinine level of 0.9 mg/dL, and normal urinary sediments. 2-4. Which treatment method would you select for further treatment of this patient?
A 39-year-old woman patient visited the hospital due to generalized edema. She was diagnosed with class V LN in a biopsy. She received a high-dose steroid and cyclosporine combination therapy. The steroid dose was gradually reduced. Six months later, she had a serum creatinine level of 0.7 mg/dL, a serum albumin level of 3.0 g/dL, and a 24 h proteinuria level of 1.9 g/dL.
MRI: magnetic resonance imaging, BUN: blood urea nitrogen, C3: complement3, C4: complement4, LN: lupus nephritis, CYC: cyclophosphamide, NIH: National Institute of Health statistically significant change in the distribution was found, however, after the symposium ( Figure 3A ).
Induction treatment of class III and IV LN
Results of the first survey: The second case was about induction treatment after the diagnosis of class IV LN via biopsy (Table 2 -2). The 25-year-old woman patient had abnormal creatinine level and 4.5 g/day proteinuria. Fifty percent (n=24) of the participants replied that they would intravenously (IV) administer high-dose CYC as the first-line treatment, about 35% (n=17) low-dose CYC, and 15% (n=7) MMF (Table 3 and Figure 2B ). The Eurolupus protocol was selected more often, with statistical significance, by the physicians who had five years experience or more (p=0.003). Regarding the evidence needed for drug selection, 52% (n=25) and 27% (n=13) of the participants replied that they would select the drug to be used for LN treatment based on the published results of clinical studies and the recent international clinical guidelines, respectively.
Comparison of the results of the first and second surveys:
There were no statistically significant differences between the answers in the first survey and those in the second. More physicians, however, selected high-dose cyclophosphamide than MMF for the initial induction treatment after the symposium ( Figure 3B ).
Maintenance treatment of LN
Results of the first survey: A case of drug selection for the maintenance treatment of class IV LN patients who were responsive to the induction treatment was presented to the symposium participants (Table 2- AZAand steroids (29%, n=14). In addition, about 21% (n=10), 10% (n=5), 6% (n=3), and 2% (n=1) of the participants would consider AZA, MMF, CYC, and cyclosporine with steroid combination therapy, respectively (Table 3 and Figure 2C ).
Regarding the evidence needed for selecting the drug to be Figure   3C ). This result showed that an agreement has been reached based on the evidence reported in the symposium.
Treatment of class V LN
Results of the first survey: A case of induction treatment of class V LN was presented to the symposium participants. A 160 Young Bin Joo et al. (Table 3 and Figure 2D ). Regarding the evidence needed for the selection of the drug to be used for the maintenance treatment of class V LN, 58% (n=28) would select the drug based on the results of clinical studies published in scientific literature.
Comparison of the results of the first and second surveys:
Before the symposium, the frequency of tacrolimus selection and the frequency of the answers in favor of the maintenance of the current treatment were similar (34 and 30%, respectively). After the symposium, the frequency of tacrolimus selection increased to 75% ( Figure 3D ). This result showed that after the symposium, some participants opted to administer a second regimen treatment for class V LN that was non-responsive to the initial treatment.
Discussion
Regarding the four important issues that draw attention in the treatment of LN, the physicians mainly expressed the following opinions. In the first survey, the physicians replied that cannot be readily performed (7) . Considering this recommendation, renal biopsy should not be hesitated although high dose steroid were already given to patients with LN.
In the survey, 85% of the respondent physicians replied that 
Conclusion
The results of this study showed that the Korean physicians agree to a considerable portion of the ACR or EULAR recommendations. They were shown to be confused, however, with regard to how to select therapeutic drugs for LN in actual clinical practice considering the ethnic difference or insurance problem. Although this study did not suggest or recommend concrete guidelines for the treatment of LN, its results could be helpful in reaching a decision with regard to the LN treatment that is most appropriate for Korean medical situations.
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Symposium on the treatment of LN
The results of the systematic review were as follows: tematic reference review (21) . Three studies that compared CYC administration with MMF administration showed no significant difference in efficacy and safety. Three other studies showed that MMF administration is more efficacious and safe.
Studies regarding the CYC doses showed that the adverse events were fewer in the low-dose case than in the high-dose case. Seven studies on tacrolimus showed that it is both efficacious and has few adverse events (22) . MMF, tacrolimus, and rituximab (18, 23, 24) .
